Leerink Partnrs Issues Negative Outlook for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities researchers at Leerink Partnrs cut their Q1 2025 earnings estimates for CRISPR Therapeutics in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.35) per share for the quarter, down from their previous estimate of ($1.25). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.45) EPS, FY2025 earnings at ($5.58) EPS and FY2026 earnings at ($5.50) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

CRSP has been the topic of a number of other reports. The Goldman Sachs Group reduced their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a report on Wednesday, February 12th. Stifel Nicolaus decreased their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. Royal Bank of Canada cut their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Finally, Barclays raised their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $73.11.

CRISPR Therapeutics Stock Down 0.0 %

Shares of CRSP stock opened at $37.77 on Friday. The firm has a market cap of $3.24 billion, a P/E ratio of -8.64 and a beta of 1.85. The business has a 50-day moving average price of $40.97 and a two-hundred day moving average price of $43.81. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $67.88.

Insider Activity

In related news, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock valued at $1,608,243 in the last 90 days. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Magnetar Financial LLC bought a new position in CRISPR Therapeutics in the fourth quarter worth approximately $359,000. Capital Market Strategies LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $461,000. Vanguard Group Inc. lifted its holdings in CRISPR Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock valued at $68,329,000 after purchasing an additional 10,579 shares in the last quarter. KBC Group NV boosted its position in shares of CRISPR Therapeutics by 2,047.4% in the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock worth $2,382,000 after purchasing an additional 57,696 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter worth $3,231,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.